Found 24 clinical trials
A Phase 1 Randomized, Observer-blind, Dose-escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an mRNA-based Monovalent Influenza Vaccine Candidate in Healthy Younger and Older Adults
The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine
- 0 views
- 24 Oct, 2022
- 4 locations
Effect of Dietary Protein on the Regulation of Exosome microRNA Expression in Patients With Insulin Resistance.
of protein-coding transcripts, this interaction leading to translational repression by destabilizing the messenger RNA. Evidence demonstrates an association between differences in miRNA expression
- 0 views
- 04 Oct, 2022
- 2 locations
Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen (CoviCompare_J)
severe COVID-19 cases, since older people are particularly at risk. Two CoviCompare studies with two licensed vaccines messenger RNA vaccines (Pfizer, Moderna) are underway to evaluate the immune
- 27 views
- 12 May, 2022
- 5 locations
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
This study evaluates the addition of Tenofovir and Entecavir in the treatment of Hepatitis B-related hepatocellular carcinoma after curative resection in adults. Half of participants will receive Tenofovir disoproxil fumarate, while the other half will receive Entecavir.
- 0 views
- 24 Jan, 2021
- 1 location
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
This trial is being completed to understand whether people with a history of an adverse reaction to the first or second dose of either the Pfizer-BioNTech COVID-19 vaccine or the Moderna COVID-19 vaccine can safely tolerate an additional dose or if individuals with a personal history of allergic reaction who …
- 0 views
- 13 May, 2022
- 1 location
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
(chimpanzee adenovirus [ChAd] and self-amplifying messenger RNA [samRNA] vectors), in combination with checkpoint inhibitors. Antitumor activity will be based on molecular response in patients with colon
- 0 views
- 04 Oct, 2022
- 3 locations
COVID Protection After Transplant-Immunosuppression Reduction (CPAT-ISR)
This study will enroll individuals who have: Completed, at a minimum, a full 2-dose course but no more than 4 of either the Moderna messenger RNA (mRNA) based coronavirus
- 0 views
- 10 Jul, 2022
- 14 locations
Meclizine for Hepatocellular Carcinoma (OPTIM)
candidates for surgical resection, ablation, TACE, Y90 or systemic therapy by blocking tumorigenesis and inducing apoptosis. The effects of Meclizine will be analyzed by measuring messenger RNA level of CAR
- 19 views
- 04 Oct, 2022
- 5 locations
NADPH Oxidase Correction in mRNA Transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells.
- 0 views
- 27 Oct, 2022
- 1 location
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
- 68 views
- 09 Mar, 2022
- 17 locations